Protara Therapeutics Sees Significant Stock Surge Following Positive Phase 2 Trial Results for TARA-002 in Bladder Cancer

High Response Rate:
TARA-002 demonstrated a 72% six-month complete response rate and a 70% complete response rate at any time across different BCG exposures in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC)235.

Safety Profile:
The therapy showed a favorable safety profile with no severe treatment-related adverse events reported. Most adverse events were mild and transient, such as flu-like symptoms and urinary tract-related issues235.

BCG-Unresponsive Patients:
In BCG-unresponsive patients, TARA-002 achieved a 100% six-month landmark complete response rate and an 80% complete response rate at any time235.

BCG-Naïve Patients:
For BCG-naïve patients, the six-month landmark complete response rate was 64%, with a 67% complete response rate at any time235.

Reinduction Salvage Rate:
The trial reported an 80% reinduction salvage rate, with all patients maintaining a complete response from three to six months235.

Market Impact:
Protara Therapeutics' shares surged over 100% following the announcement of these positive trial results2.

Sources:

2. https://www.investing.com/news/stock-market-news/protara-therapeutics-shares-surge-on-positive-trial-results-93CH-3756929

3. https://www.stocktitan.net/news/TARA/protara-announces-positive-results-from-the-ongoing-phase-2-advanced-uz2t2xyowihh.html

5. https://ir.protaratx.com/news-releases/news-release-details/protara-announces-positive-results-ongoing-phase-2-advanced-2